# ACE-2-like enzymatic activity is associated with immunoglobulin in COVID-19 patients

Yufeng Song[1], Regan Myers[1], Lila Murphy[1,2], Bailey Brooks[1,2], Jeffrey M. Wilson[3], Alexandra Kadl[4,5], Judith Woodfolk[4],Steven L. Zeichner[1,6]*

[1]Department of Pediatrics, University of Virginia

[2]College of Arts and Sciences, University of Virginia

[3]Division of Allergy and Clinical Immunology, Department of Medicine, University of Virginia

[4]Department of Medicine, University of Virginia

[5]Department of Pharmacology, University of Virginia

[6]Department of Microbiology, Immunology, and Cancer Biology, University of Virginia

*Correspondence: zeichner@virginia.edu

## Abstract

Many mechanisms responsible for COVID-19 pathogenesis are well-established, but COVID-19 includes features with unclear pathogenesis, such as autonomic dysregulation, coagulopathies, and high levels of inflammation. The receptor for SARS-CoV-2 spike protein's receptor binding domain (RBD) is angiotensin converting enzyme 2 (ACE2). We hypothesized that some COVID-19 patients may develop antibodies that have negative molecular image of RBD sufficiently similar to ACE2 to yield ACE2-like catalytic activity – ACE2-like abzymes. To explore this hypothesis, we studied patients hospitalized with COVID-19 who had plasma samples available obtained about 7 days after admission. ACE2 is a metalloprotease that requires $Zn^{2+}$ for activity. However, we found that the plasma from some patients studied could cleave a synthetic ACE2 peptide substrate, even though the plasma samples were collected using disodium ethylenediaminetetraacetate (EDTA) anticoagulant. When we spiked plasma with synthetic ACE2, no ACE2 substrate cleavage activity was observed unless $Zn^{2+}$ was added or the plasma was diluted to decrease EDTA concentration. After processing samples by 100 kDa size exclusion columns and protein A/G adsorption, which depleted immunoglobulin by >99.99%, the plasma samples did not cleave the ACE2 substrate peptide. The data suggest that some patients with COVID-19 develop antibodies with abzyme-like activity capable of cleaving synthetic ACE2 substrate. Since abzymes can exhibit promiscuous substrate specificities compared to the enzyme whose active site image they resemble, and since proteolytic cascades regulate many physiologic processes, anti-RBD abzymes may contribute to some otherwise obscure COVID-19 pathogenesis.

## Introduction

The primary pathology in COVID-19 involves pulmonary disease[1-3]. Other end organ involvement, likely directly attributable to infection with the virus, can include gastrointestinal disease, such as diarrhea, and loss of smell and taste[2-4]. While the basic pathophysiology of COVID-19 is well-established, COVID-19 has many baffling features, including disorders involving high inflammation, disorders of the clotting cascade, and problems with blood pressure homeostasis[2, 5, 6]. Some sequelae do not develop until a week or more after infection, suggesting that their pathogenesis may result from secondary processes.

Reports suggest that some of the inflammatory processes associated with COVID-19 may relate to antibodies against the SARS-CoV-2 spike protein, S. For example, small numbers of children who have received COVID-19 vaccines and have had no evidence of infection with SARS-CoV-2, as well as a small number of infants born to mothers with COVID-19[8] have been described as having multi-system inflammatory syndrome of children (MIS-C)[7].

In addition to acute COVID-19, some patients experience Post-Acute Sequelae of SARS CoV-2 infection (PASC, sometimes called “long COVID”), a heterogeneous group of symptoms that continue after acute infection has resolved and can include evidence of a hyperinflammatory state[9], persistent coagulopathies, and neurophysiologic dysregulation, for example aberrant blood pressure regulation. While some clinical features observable at the beginning of the COVID-19 clinical course, such as SARS-CoV-2 viremia, autoantibodies, inflammatory markers, and activation of Epstein-Barr

71 Virus, may be associated with an increased risk of long COVID[10], the detailed
72 pathogenic processes responsible for PASC remain unclear.
73
74 Membrane-bound angiotensin converting enzyme 2 (ACE2) is the main cellular receptor
75 for SARS-CoV-2. Binding of the SARS-CoV-2 spike protein receptor binding domain
76 (RBD) to ACE2 initiates the pathway that leads to infection of a new host cell. ACE2, a
77 $Zn^{2+}$ metalloenzyme, cleaves angiotensin II into angiotensin 1-7, which has vasodilatory
78 activity. Angiotensin converting enzyme (ACE) cleaves angiotensin I to yield angiotensin
79 II, which has vasoconstrictive and hypertensive effects. ACE2 therefore helps to
80 counteract the hypertensive effects of angiotensin II, and so has blood pressure
81 counterregulatory activity compared to ACE. There have been isolated reports and
82 small case series describing persistent hypotension in patients with COVID-19 and
83 patients with PASC without a clearly identified cause[11-13].
84
85 The kallikrein-kinin system is a proteolytic cascade that helps regulate inflammation
86 (reviewed in [14]). There is cross-talk between the coagulation, kallikrein-kinin,
87 complement and renin-angiotensin systems[15]. Some patients with severe COVID-19
88 respiratory disease have been found to have altered regulation of the kallikrein-kinin
89 system in bronchoalveolar lavage fluid[16]. Abnormalities in the kallikrein-kinin system
90 have been proposed as contributing to the pathogenesis of severe COVID-19[17].
91
92 Catalytic antibodies, “abzymes”[18, 19], are antibodies that have catalytic activity. When
93 abzymes were first described, they generated considerable excitement. Investigators
94 hypothesized that it would be possible to produce clinically and biotechnologically useful
95 abzymes.

However, with additional studies, it became clearer that abzyme activity was significantly lower than the activity of more conventional enzymes (*k*cat/*Km* values ~$10^2$ - $10^4$ $s^{-1}$•M $s^{-1}$ [20] vs. *k*cat/*Km* values of ~$10^5$ $s^{-1}$•M $s^{-1}$)[21]. Hence, interest in the biotechnological applications of abzymes waned, but an appreciation of the potential role of abzymes in the pathogenesis of disease, including autoimmune disease, increased. High concentrations of abzymes in the circulation may compensate for the abzymes' lower activity to yield clinically significant effects.

Patients with autoimmune diseases can make abzymes catalyzing, for example, cleavage of vasoactive intestinal peptide (VIP)[22], DNA[23], immunoglobulin components[24], components of the clotting cascade[25-27], and myelin basic protein (MBP) in patients with multiple sclerosis[28]. Abzymes that cleave the HIV envelope protein have been observed to occur in patients with HIV, so there is precedence for the induction of a catalytic antibody by a virus[29].

Investigators have deliberately made anti-idiotypic abzymes with catalytic activity like the activity of a particular enzyme of interest[30, 31]. Investigators identify an antibody against an enzyme, and then produce an antibody against the anti-enzyme antibody. For some of the anti-idiotypic antibodies, there is enough resemblance to the active site of the enzyme that the anti-idiotypic antibody has catalytic activity resembling the enzyme[32, 33]. In some instances, the substrate specificity of the abzyme differs substantially from that of the original enzyme[31, 32, 34], with the abzyme showing more substrate promiscuity than the original enzyme.

121 The receptor binding domain of the SARS-CoV-2 spike protein uses the ACE2 enzyme
122 on the surface of the target future host cell as its receptor. The RBD is not an antibody,
123 but it does bind ACE2. Taking as an example of abzyme production the anti-idiotypic
124 antibody to an antibody against an enzyme, it is plausible to hypothesize that in some
125 cases, an antibody against the RBD might resemble the ACE2 active site and so have
126 catalytic activity. If an antibody directed against the RBD has some resemblance to
127 ACE2, it is also plausible that anti-RBD antibodies, for some small fraction of patients,
128 might have catalytic activity reminiscent of ACE2. We hypothesized that some COVID-
129 19 patients may develop anti-RBD antibodies, with promiscuous catalytic activity that, in
130 some cases, cleaves substrates in patients to yield clinically significant effects. FIG 1
131 outlines this hypothesis schematically. We therefore undertook a study to explore
132 whether some COVID-19 patients might have antibodies that can cleave an ACE2
133 substrate.
134
135 We studied plasma samples from a group of 67 patients, with samples obtained
136 relatively early in their disease course, on about the 7th day of hospitalization. We
137 tested plasma using an established fluorometric assay for ACE2 activity, which detects
138 cleavage of an ACE2 peptide substrate. We found that some of the patients had ACE2
139 substrate peptide cleavage activity when the assay was run directly on disodium
140 ethylenediaminetetraacetate (EDTA)-anticoagulated plasma samples, even though
141 ACE2 is a metalloprotease that requires $Zn^{2+}$ for activity. Recombinant ACE2 added to
142 plasma did not show ACE2 substrate-cleaving activity unless $ZnCl_2$ was added to
143 samples at concentrations greater than the EDTA. Processing the samples through a
144 100 KDa size exclusion column followed by absorption with protein A/G beads, which
145 depleted IgG by >99.99%, eliminated the ability of the samples to cleave the ACE2

146 peptide substrate, supporting the hypothesis that a fraction of COVID-19 patients may

147 develop antibodies that have ACE2 substrate cleavage activity.

148

149

150 # Methods

151 ## Clinical Cohort

152 The clinical cohort was recently described in more detail in another publication[35]. The
153 hypothesis motivating that work held that COVID-19 would lead to large scale
154 reactivation of lymphotrophic herpesviruses EBV and HHV-6, but the data obtained in
155 the study did not support that hypothesis. In brief, the University of Virginia (UVA)
156 enrolled a prospective cohort of moderate to severe COVID-19 adult patients admitted
157 to the hospital with a diagnosis confirmed by a nucleic acid amplification test. Patients
158 consented were entered into the study. Clinical data were entered into study databases.
159 Plasma was collected into clinical standard lavender top (EDTA anticoagulant) tubes.
160 Samples were processed in the UVA Biorepository and Tissue Facility and stored at -80
161 C. Study participants (n=67) were adults ages 18 years and above. We used samples
162 obtained on or about day 7 of hospitalization for this study, prior to anti-inflammatory
163 drug administration. The predominant viral strain for our sample was the alpha strain
164 with 98.51% of our sample (66 patients) being collected before July of 2021.The sample
165 collection protocol was approved by the UVA IRB (HSR #200110), and approval was
166 obtained to work on the specimens (HSR #HSR200362), and it follows the
167 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
168 guidelines. EDTA-anticoagulated healthy normal donor plasma was purchased from
169 Valley Biomedical (Cat. #HP1051P), aliquoted and stored in -20℃ according to
170 manufacturer's instructions.

171

172 ## Angiotensin II Converting Enzyme (ACE2)-like Abzyme Activity Detection

173 Abzyme catalytic activities in plasma samples were measured using an Angiotensin II
174 Converting Enzyme (ACE2) Activity Assay Kit, Fluorometric (Abcam, Cat. #ab273297)

175 according to the manufacturer's protocol. This assay employs a synthetic ACE2 peptide
176 substrate labeled with a fluor and a quencher. The manufacturer's product information
177 claims a lower limit of detection for an unmodified assay of 400 μU. The manufacturer
178 does not release detailed information concerning the peptide substrate, holding that
179 information as a trade secret. The kit includes recombinant human ACE2 (ACE2) for
180 use as a positive control. 50$\mu$l plasma was added to wells in a 96-well black flat bottom
181 assay plate (Corning, Cat. #3603) and incubated at room temperature (RT), in the dark
182 for 15 min. Then, 50$\mu$l of substrate pre-diluted according to manufacturer's protocol was
183 added into the wells of the plate, mixing the substrate with the plasma sample. The
184 plate was immediately placed into a SpectraMax® M5 multi-model microplate reader
185 (Molecular Devices) and the Relative Fluorescent Unit (RFU, Ex/Em = 320/420 nm)
186 values were measured in kinetic mode every 20 min for a total of 16 hours at 37℃.
187 ACE2 inhibitor provided in the assay kit was also used for additional controls.
188
189 **Determination of ACE2 Substrate Peptide Cleavage Activity in Plasma Samples**
190 **With and Without Added $ZnCl_2$ or Plasma Dilution**
191 To evaluate whether native ACE2 shed into blood[36, 37] could contribute to the catalytic
192 activity observed in the patient plasma samples, we investigated whether EDTA present
193 in the plasma samples inhibited activity of recombinant ACE2 spiked into the samples.
194 EDTA can inhibit the catalytic activity of ACE2, a $Zn^{2+}$ metaloprotease[38, 39].
195
196 We conducted serial 10-fold dilutions of the normal donor plasma in ACE2 assay buffer
197 from the assay kit and then added and then added 2 $\mu$L recombinant positive control
198 ACE2, provided as a positive control in the ACE2 assay kit (Abcam, Cat. #ab273297) to
199 each well to the samples to the samples according to the manufacturer's protocol,

200 conducting the ACE2 assays on the serially diluted samples with the added
201 recombinant ACE2. We also added $ZnCl_2$ to some samples to achieve final
202 concentrations ranging from 0 to 2 mM. Samples containing plasma, recombinant ACE2
203 and $ZnCl_2$ mixture with pre-diluted ACE2 inhibitor served as negative comparisons.
204 Then, 50 $\mu$L of substrate (pre-diluted according to manufacturer's protocol) was added
205 into the wells. Relative Fluorescent Units were measured, and data was analyzed as
206 described below.
207
208 **Human IgG Depletion and Detection**
209 To deplete immunoglobulin from the samples, patient plasma samples or pooled healthy
210 donor plasma were centrifuged at 12,000 g at 4 ℃ for 15 min and supernatants were
211 passed through 0.45 $\mu$m syringe filter (FisherScientific, Cat. #97204) to remove
212 contaminating particulate matter. We then placed 500 $\mu$L of the filtered samples into
213 ultrafiltration columns with 100kDa cut-off ultrafiltration membrane (Pierce™ Cat. #
214 88503) and centrifuged the columns at 12,000 × g at 4 ℃ until > 400 $\mu$L of filtrate was
215 produced. To further deplete antibodies in the plasma samples, we then incubated the
216 flow-through fractions with 30 $\mu$L pre-washed Protein A/G Magnetic Beads (Life
217 Technologies, Cat. # 88803, 10 mg/mL) at room temperature (RT) for 1 hour, followed
218 by magnetic removal of the beads, and repeated the same incubation procedure with
219 another freshly prepared 30 $\mu$L magnetic beads. The resulting processed plasma
220 samples were stored at 4℃ for short times (less than 12 hours) or -20 ℃ for longer
221 times. Human IgG was measured using a Human IgG ELISA Kit (Abcam, Cat.
222 #ab100547) according to the manufacturer's protocol. We added 50 $\mu$L processed
223 samples, as well as standards to multi-microwell strips and incubated them at room
224 temperature for 2.5 hours. Strips were washed with wash buffer and 50 $\mu$L diluted

225 biotin-labeled IgG detection antibody were then added to each well with subsequent
226 HRP-streptavidin incubation after another wash step. Each incubation was performed at
227 room temperature for at least 1 hour. After washing, 100 $\mu$L of TMB One-Step Substrate
228 was added to each well and was incubated for 5 to 15 min at room temperature in the
229 dark with gentle shanking. The reaction was stopped by adding 50 $\mu$L Stop Solution to
230 each well. OD values were read at 450 nm using an accuSkan FC micro-well plate
231 reader (ThermoFisher). IgG concentrations were calculated based on standard curves
232 generated with the same batch of assay strips.
233
234 **Data Analysis**
235 Since the RFU values for the assays conducted on the samples reached 80% of
236 maximum at about 240 min, RFU values observed over 240 min generated by an ACE2
237 kit were used to evaluate ACE2 substrate cleavage activity in the plasma samples. For
238 each sample, a value corrected for baseline fluorescence in the sample was obtained
239 by the subtracting the baseline RFU value from the value at each subsequent time and
240 the sum of the baseline-corrected RFU values over 240 min was calculated using Excel.
241 Subsequent statistical analysis and data visualization was done using R (version 4.2.1)
242 with the Rstudio environment and packages ggplot2, tidyverse, readr, drc, ggpubr,
243 ggh4x, gridExtra, and scales. Raw data and R scripts used in the analysis are provided
244 in Supplementary Data (S1, S2). Samples with the top 20% and a control bottom 10%
245 RFU values over 240 min were identified for antibody depletion and further assays.
246
247

248 **Results**

249 To develop assays with enhanced sensitivity for ACE2 substrate cleavage activity, we
250 used a commercially available kit, in which a synthetic peptide ACE2 substrate labeled
251 with a fluor and a quencher is exposed to sample. ACE2 substrate cleavage activity
252 frees the fluor from quenching, followed by fluorometric evaluation over time. We first
253 established the kit's performance characteristics on commercially purchased EDTA-
254 anticoagulated normal human plasma. ACE2 is as $Zn^{2+}$-requiring metalloenzyme. Since
255 EDTA was used as the anticoagulant, to make $Zn^{2+}$ unavailable to the $Zn^{2+}$-requiring
256 metalloenzymes of the enzymes involved in the coagulation cascade, we first
257 established whether exogenously added ACE2 could be detected when added to
258 plasma samples under our assay conditions. We found that exogenously added
259 recombinant ACE2 could not be detected, either using commercially obtained pooled
260 plasma or in plasma samples pooled from our patients and obtained from our sample
261 bank, unless $Zn^{2+}$ was added or unless the plasma was diluted (FIG 2). Since no native
262 ACE2 activity should be detectable in the EDTA-anticoagulated plasma, any ACE2
263 substrate cleavage activity observed in the EDTA-anticoagulated plasma should be due
264 to something other than ACE or another $Zn^{2+}$ metalloprotease.

265

266 We performed the ACE2 assay on EDTA-anticoagulated (obtained using clinical
267 standard lavender top tubes) research participant plasma samples obtained at about the
268 $7^{th}$ day of hospitalization for a cohort of 67 COVID-19 patients with moderate to severe
269 disease. Using these samples, without dilution and without added $Zn^{2+}$, we found that
270 we could detect cleavage of the ACE2 peptide substrate in some of the patients,
271 suggesting that the ACE2 peptide substrate cleavage activity was produced by an agent

272 with co-factor characteristics different from canonical ACE2 (FIG 3). FIG 4 shows a
273 scatter plot of the RFU values for the 67 patients studied.
274
275 To determine whether the ACE2 substrate cleavage activity was associated with the
276 presence of immunoglobulin in the samples, we developed an immunoglobulin depletion
277 protocol that includes an initial 0.45 um filtration step to remove large aggregates,
278 followed by a 100 KDa size exclusion column chromatography step, and a subsequent
279 staphylococcal A/G bead absorption step. To test whether patients with high RFU had
280 ACE2 substrate cleavage activity associated with immunoglobulin, we selected samples
281 from patients who had RFU values in the top 20% RFU values and which still had
282 sufficient plasma samples remaining for the immunoglobulin depletion procedure and
283 subsequent ACE2 assays. This selection yielded samples from 11 patients, 4, 5, 9, 11,
284 13, 15, 27, 43, 44, 47, and 48. We also selected samples from 3 patients (17, 64, 64)
285 who were among the patients having the bottom 10% of ACE2 substrate cleavage
286 activity and for which sufficient sample was available for the immunoglobulin depletion
287 procedure as negative control. We also included a purchased pooled EDTA-
288 anticoagulated plasma sample as an additional control.
289
290 Table 2 show the results of the immunoglobulin depletion protocol applied to the patient
291 plasma samples from these patients. The process depleted IgG by a factor of
292 >>99.99%, leaving IgG in the samples at <2.5 ng/ml for all samples.
293
294 We then re-assayed these samples to determine whether immunoglobulin depletion
295 was associated with elimination of the ACE2 substrate cleavage activity (FIG 5), and
296 found that for the 11 tested patients with ACE2 substrate cleavage activity in this cohort,

297 depletion of the immunoglobulin was accompanied by elimination of ACE2 substrate

298 cleavage activity.

299

300 **Discussion**

301 Our experiments indicate that a fraction of patients with COVID-19 have an activity in
302 plasma capable of cleaving a substrate for ACE2. The ACE2 substrate cleavage activity
303 has divalent cation requirements different from native ACE2 and collocates with
304 immunoglobulin presence during an immunoglobulin depletion procedure, suggesting
305 that these patients may have antibodies with abzyme activity. Since abzymes can have
306 a broadened substrate specificity compared to the original enzyme that they mirror, it is
307 possible that abzymes made in response to SARS-COV-2 infection may be able to
308 cleave a range of substrates, including substrates that form components of important
309 regulatory cascades, like clotting, blood pressure regulation, and inflammation
310 processes, which could account for aspects of COVID-19 that cannot be directly
311 attributed to viral infection and cell and tissue destruction.

312

313 Our study had several strengths. We studied a moderate number of patients, with
314 samples collected prospectively from acutely hospitalized patients with clearly
315 established COVID-19 relatively early in their disease course, but likely approaching at
316 least 2 weeks following initial infection. The patients almost certainly were not admitted
317 immediately following initial infection and the samples were obtained about a week after
318 admission, providing enough time for the development of an initial antibody response to
319 SARS-CoV-2 infection. We used a standard, widely-employed kit for ACE2 peptide
320 substrate cleavage activity, standard size exclusion columns, protein A/G bead
321 absorption immunoglobulin depletion techniques, and assays for immunoglobulins. The
322 data showing that the ACE2 substrate cleavage activity was present even when there
323 was sufficient EDTA to chelate the $Zn^{2+}$ essential for ACE2 activity suggests that the
324 ACE2 substrate cleavage activity had important characteristics different from native

325 ACE2. The data that the ACE2 substrate cleavage activity was removed from the
326 samples following processing with size exclusion columns and absorption with protein
327 A/G beads suggests that the non- $Zn^{2+}$-requiring ACE2 substrate cleavage activity co-
328 localizes with immunoglobulin, supporting the hypothesis that the patients with ACE2
329 substrate cleavage activity may have developed abzymes with this activity.
330
331 However, our study has several limitations. We only studied a limited subset of the
332 patients admitted to our hospital, from patients who consented to the sample banking
333 and study and for whom sufficient sample volumes were available. A
334 contemporaneously collected, matched, prospective set of samples from patients
335 without COVID-19 would have been ideal negative controls, but samples from such
336 subjects were not obtained as part of the sample banking effort. We also only
337 conducted the assays on patient samples obtained at a single time, about 7 days after
338 hospitalization, so we have no data from patients who were discharged, transferred, or
339 died prior to day 7 of hospitalization. More importantly, in this study we have no data
340 from patients later in their disease course or following convalescence from the acute
341 disease. Inflammatory, coagulopathic, and physiologic dysregulatory phenomena
342 predominate in the later stages of COVID-19 and at least some aspects of PASC and
343 MIS-C appear to result from immune-mediated phenomena. However, some of these
344 patients are treated with anti-inflammatory agents, including intravenous
345 immunoglobulin, which would make the study of these patients for abzyme-like activity
346 difficult. If abzymes with promiscuous substrate specificities develop in some COVID-19
347 patients, some of the clinical features of those disorders could potentially be attributed
348 to abzymes, but this study is not able to directly address such additional hypotheses,
349 which would require additional work. In addition, since abzymes can show substantial

350 substrate specificity spread, it is possible that additional patients in our cohort had
351 abzymes with substrate specificity sufficiently divergent from angiotensinogen that it
352 was not detectable using our assay. It is also possible that COVID-19 patients develop
353 anti-RBD antibodies with abzyme-like activity, but that these antibodies have no clinical
354 significance. Some fraction of normal individuals may have ACE2-like abzyme activity,
355 but this activity could have been diluted in the purchased pooled normal control plasma.
356 However, if the abzyme activity in such patients was similar to that observed in the
357 individual positive patients in this study, that activity would still be ~15% of the activity of
358 the positive patients, given the prevalence of detectable abzyme activity in our cohort,
359 and so would have been likely detectable.
360
361 Finally, our study is merely associational. It is possible that we depleted some other,
362 non-immunoglobulin component of COVID-19 patient plasma that has the ability to
363 cleave the ACE2 substrate peptide with our 100 kDa size exclusion plus protein A/G
364 treatment procedure. To unequivocally establish that some COVID-19 patients develop
365 anti-SARS-CoV-2 immune responses that include abzymes, it would be necessary to
366 isolate discrete monoclonal antibodies from patients with ACE2 substrate cleavage
367 activity, and then characterize those monoclonal antibodies in detail. Such work lies
368 outside the perimeters of this current study.
369
370 Nevertheless, our study offers potential additional insight into some of the difficult-to-
371 understand clinical features of COVID-19, and if some of the difficult manifestations of
372 COVID-19 are related to the induction of antibodies with abzyme-like activity, that
373 finding may suggest new therapeutic interventions. Some other viruses also have also
374 evolved to use enzymes located on the target host cell surface as their receptors, so it

375 is conceivable that those other viral infections may also elicit clinically problematic anti-
376 viral antibodies. The number of spike protein RBDs presented to the immune system in
377 a natural infection is vastly greater than the number of RBDs presented to the immune
378 system following vaccination, offering many more opportunities for the induction of wide-
379 ranging antibody responses, unlike the antigen exposure resulting from vaccination.
380 While complications following vaccination are very rare and the risk-benefit calculation
381 greatly favors vaccination, some of the adverse side effects of SARS-CoV-2 vaccines
382 might also be attributable to the rare induction of anti-RBD antibodies with catalytic
383 activity.
384
385 **Institutional Review Board Statement:** The sample collection protocol was approved
386 by the UVA IRB (HSR #200110), and approval was obtained to work on the specimens
387 (HSR #HSR200362).
388
389 **Informed Consent Statement:** Informed consent was obtained from all participants
390 involved in the study.
391 **Data Availability Statement:** Data is presented in the manuscript and the
392 supplements. Raw data can be obtained on request.
393
394 **Acknowledgments and Funding:** The study was supported by internal funding from
395 the University of Virginia, including the Manning Fund for COVID-19 Research at UVA
396 the Ivy Foundation, the Pendleton Laboratory Fund for Pediatric Infectious Disease
397 Research, and the Coulter Foundation, with sample acquisition costs supported by the
398 HHV-6 Foundation. We thank the study participants for graciously agreeing to be
399 research participants, and the research support staff who enrolled the study participants

(led by Linda Bailes RN, Allison Raymond RN and Sarah Struchen RN). We also thank the University of Virginia Biorepository and Tissue Research Facility for processing the samples used in the study and for providing specimens (Technical Director, Patcharin Pramoonjago PhD).

**Conflicts of Interest:** The authors declare no conflict of interest.

407 **Tables and Figures**
408
409
410

**Table 1. Patient Demographic and Clinical Characteristics (cohort previously described in [35])**
(IQR: interquartile range)

| **Characteristic** | **N = 67,** median, (IQR) |
|---|---|
| *Age at Admission* | 60 (48, 66) |
| *First Weight (kg)* | 91 (76, 112) |
| Unknown | 1 |
| *Height (m)* | 1.68 (1.60, 1.83) |
| Unknown | 6 |
| *Gender* | |
| Female | 28 (42%) |
| Male | 39 (58%) |
| *Race* | |
| African American | 23 (34%) |
| Native American | 1 (1.5%) |
| Caucasian | 31 (46%) |
| Other | 12 (18%) |
| *Smoking Status* | |
| Current | 1 (2.1%) |
| Former | 14 (29%) |
| Never | 24 (50%) |
| Unknown | 9 (19%) |
| NA | 19 |
| *Need for ICU* | |
| No | 28 (42%) |
| Yes | 39 (58%) |
| *Need for Intubation* | |
| No | 41 (61%) |
| Yes | 26 (39%) |
| *Blood Type* | |
| A- | 2 (4.8%) |
| A+ | 14 (33%) |
| AB+ | 1 (2.4%) |
| B+ | 3 (7.1%) |
| O- | 1 (2.4%) |
| O+ | 21 (50%) |
| Not determined | 25 |
| *Highest Temperature* | |
| <38 | 42 (49%) |
| 101 | 12 (18%) |
| >38.5 | 12 (18%) |
| >40 | 1 (1.5%) |
| *Length of Stay (Days)* | 10 (5, 22) |
| *Time to Death (Days)* | |
| 6 | 1 |
| 10-20 | 2 |
| 20-30 | 3 |
| >30 | 2 ( |
| *Highest D-Dimer* | 605 (280, 2,074) |
| *Highest CRP* | 10 (4, 16) |
| *BMI* | 33 (27, 38) |
| *Need for Vasopressors* | |
| Yes | 44 (66%) |
| *Dexamethasone* | |
| Yes | 41 (61%) |
| *Prednisone* | |
| Yes | 3 (13%) |
| *Methylprednisolone* | |
| Yes | 5 (22%) |
| *Tocilzumab* | |
| Yes | 4 (6%) |
| *Remdesivir* | |
| Yes | 27 (40%) |
| *Creatinine* | 1.00 (0.80, 1.45) |
| *Hgb* | 12.4 (10.8, 13.6) |
| *IFNa3* | 45 (36, 72) |
| Not determined | 45 |
| *Highest Ferritin* | 1277 (7, 7161) |
| Not determined | 5 |
| *Highest Troponin* | |
| <0.04 | 47 (73%) |
| 0.04-0.4 | 12 (18%) |
| >0.6 | 3 (5%) |
| Not determined | 5 |
| *Highest Creatinine* | 1.10 (0.90, 1.80) |

Table 2. Plasma IgG concentration before and after antibody depletion for selected patients exhibiting ACE2 substrate cleavage activity in FIG 2, then re-assayed for ACE2 substrate cleavage activity with results shown in FIG 4.

| Patient (#) | IgG Concentration | | IgG depletion efficiency (%) |
|---|---|---|---|
| | Pre[a] mg/ml | Post[b] ng/ml | |
| 4 | 14.62 | 0.67 | >99.99% |
| 5 | 12.50 | 1.48 | >99.99% |
| 9 | 24.40 | 0.96 | >99.99% |
| 11 | 75.41 | 0.17 | >99.99% |
| 13 | 26.35 | 2.46 | >99.99% |
| 15 | 13.27 | 2.47 | >99.99% |
| 27 | 10.53 | 2.40 | >99.99% |
| 43 | 29.07 | 0.87 | >99.99% |
| 44 | 11.17 | 2.29 | >99.99% |
| 47 | 13.15 | 1.85 | >99.99% |
| 48 | 12.32 | 2.06 | >99.99% |

a: IgG concentration in plasma before antibody depletion
b: IgG concentration in plasma after antibody depletion by ultrafiltration and Protein A/G beads

495
496 **Figure Legends**
497
498 FIG 1. Schematic diagram illustrating the hypothesis underlying the study. The SARS-
499 COV-2 Spike Protein Receptor Binding Domain (RBD) binds ACE2 on the surface of a
500 potential host cells. The RBD has a partial negative image of ACE2. Some antibodies
501 against the RBD may then have a conformation sufficiently like ACE2 to have
502 proteolytic activity similar to the proteolytic activity of ACE2. The hypothesis further
503 suggests that the catalytic activity of some antibodies will have a substrate specificity
504 like ACE2, but because the negative image of RBD present antibodies is imperfect,
505 some antibodies with proteolytic activity will have an altered substrate specificity,
506 potentially affecting multiple proteolytic regulatory cascades.
507
508 FIG 2. Inhibition of exogenously added recombinant ACE2 substrate cleavage activity in
509 undiluted EDTA-anticoagulated pooled plasma samples with and without added $ZnCl_2$.
510 ACE2 is a $Zn^{2+}$ metalloprotease. In this ACE2 spiking experiment, no ACE2 activity was
511 detectable when exogenous ACE2 was added to the plasma, unless $Zn^{2+}$ was also
512 added, or unless the plasma was diluted prior to the addition of the spiked-in ACE2.
513 Adding an ACE2 inhibitor blocked detection of the ACE2 activity in all conditions,
514 indicating that the activity was specific for ACE2. The findings indicate that no native
515 ACE2 activity should be detectable in the EDTA-anticoagulated plasma and so any
516 ACE2 substrate cleavage activity observed in the EDTA-anticoagulated plasma should
517 be due to something other than ACE or another $Zn^{2+}$ metalloprotease.
518
519 FIG 3. Survey of ACE2 substrate cleavage activity in plasma from 67 patients with
520 COVID-19 sampled at about day 7 of hospitalization. The plots present the results of the
521 fluorometric assays for ACE2 substrate cleavage activity run on the 67 patients, plus

522 control samples. Several patients, including the 11 patients we selected for further study
523 (4, 5, 9, 11, 13, 15, 27, 43, 44, 47, 48) because they had among the top 20% of RFU
524 values and had sufficient plasma sample remaining for the immunoglobulin depletion
525 protocol, showed an ability to cleave ACE2 substrate. (HDP: commercially purchased
526 pooled healthy donor plasma; HDP+P.C: HDP with added recombinant human ACE2;
527 HDP+P.C+I: HDP+P.C.+ ACE2; inhibitor; P.P.P alone: pooled plasma from negative
528 samples).
529
530 FIG 4. Scatter plot of the background corrected RFU values for the plasma samples
531 from the 67 patients evaluated in this study. The top 20% of values are plotted in red,
532 the middle 70% are plotted in black, and the bottom 10% are plotted in blue. The top
533 20% and bottom 10% were selected for the ACE2 substrate cleavage activity assays
534 before and after immunoglobulin depletion shown in FIG 5.
535
536 FIG 5. ACE2 substrate cleavage activity in patients before and after immunoglobulin
537 depletion. The figure shows ACE2 substrate cleavage activity for 11 patients (4, 5, 9,
538 11, 13, 15, 27, 43, 44, 47, 48) who had among the top 20% of RFU values and for which
539 we had sufficient plasma for immunoglobulin depletion, before (blue points) and after
540 (red points) immunoglobulin depletion by a 100 KDa size exclusion column followed by
541 protein A/G bead absorption. We also show ACE2 substrate cleavage activity assays
542 before and after immunoglobulin depletion for pooled patient plasma (PPP) negative
543 controls and samples from three arbitrarily selected patients, 17, 64, 65, that had among
544 the bottom 10% of RFU values and had sufficient plasma remaining for the
545 immunoglobulin depletion protocol. The data suggest that for the 11 patients

546 demonstrating ACE2 substrate cleavage activity in this cohort, the ACE2 substrate

547 cleavage activity was depleted in an immunoglobulin-associated manner.

548

FIG 1. FIG 1. Schematic diagram illustrating the hypothesis underlying the study. The SARS-COV-2 Spike Protein Receptor Binding Domain (RBD) binds ACE2 on the surface of a potential host cells. The RBD has a partial negative image of ACE2. Some antibodies against the RBD may then have a conformation sufficiently like ACE2 to have proteolytic activity similar to the proteolytic activity of ACE2. The hypothesis further suggests that the catalytic activity of some antibodies will have a substrate specificity like ACE2, but because the negative image of RBD present antibodies is imperfect, some antibodies with proteolytic activity will have an altered substrate specificity, potentially affecting multiple proteolytic regulatory cascades.



FIG 2. Inhibition of exogenously added recombinant ACE2 substrate cleavage activity in undiluted EDTA-anticoagulated pooled plasma samples with and without added $ZnCl_2$. ACE2 is a $Zn^{2+}$ metalloprotease. In this ACE2 spiking experiment, no ACE2 activity was detectable when exogenous ACE2 was added to the plasma, unless $Zn^{2+}$ was also added, or unless the plasma was diluted prior to the addition of the spiked-in ACE2. Adding an ACE2 inhibitor blocked detection of the ACE2 activity in all conditions, indicating that the activity was specific for ACE2. The findings indicate that no native ACE2 activity should be detectable in the EDTA-anticoagulated plasma and so any ACE2 substrate cleavage activity observed in the EDTA-anticoagulated plasma should be due to something other than ACE or another $Zn^{2+}$ metalloprotease.



FIG 3. Survey of ACE2 substrate cleavage activity in plasma from 67 patients with COVID-19 sampled at about day 7 of hospitalization. The plots present the results of the fluorometric assays for ACE2 substrate cleavage activity run on the 67 patients, plus control samples. We identified plasma from 11 patients (4, 5, 9, 11, 13, 15, 27, 43, 44, 47, 48) that showed an ability to cleave ACE2 substrate. (HDP: commercially purchased pooled healthy donor plasma; HDP+P.C: HDP with added recombinant human ACE2; HDP+P.C+I: HDP+P.C.+ ACE2; inhibitor; P.P.P alone: pooled plasma from negative samples).



FIG 4. Scatter plot of the background corrected RFU values for the plasma samples from the 67 patients evaluated in this study. The top 20% of values are plotted in red, the middle 70% are plotted in black, and the bottom 10% are plotted in blue. The top 20% and bottom 10% were selected for the ACE2 substrate cleavage activity assays before and after immunoglobulin depletion shown in FIG 5.



FIG 5. ACE2 substrate cleavage activity in patients before and after immunoglobulin depletion. The figure shows ACE2 substrate cleavage activity for 11 patients (4, 5, 9, 11, 13, 15, 27, 43, 44, 47, 48) who had among the top 20% of RFU values and for which we had sufficient plasma for immunoglobulin depletion, before (blue points) and after (red points) immunoglobulin depletion by a 100 KDa size exclusion column followed by protein A/G bead absorption. We also show ACE2 substrate cleavage activity assays before and after immunoglobulin depletion for pooled patient plasma (PPP) negative controls and samples from three arbitrarily selected patients, 17, 64, 65, that had among the bottom 10% of RFU values and had sufficient plasma remaining for the immunoglobulin depletion protocol. The data suggest that for the 11 patients demonstrating the highest ACE2 substrate cleavage activity in this cohort, the ACE2 substrate cleavage activity was depleted in an immunoglobulin-associated manner.



## References


1. Bajema KL, Oster AM, McGovern OL, Lindstrom S, Stenger MR, Anderson TC, Isenhour C, Clarke KR, Evans ME, Chu VT, Biggs HM, Kirking HL, Gerber SI, Hall AJ, Fry AM, Oliver SE. Persons Evaluated for 2019 Novel Coronavirus - United States, January 2020. MMWR Morb Mortal Wkly Rep. 2020 Feb 14;69(6):166-70. PMC7017962

2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. PMC7159299

3. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. Jama. 2020 Apr 7;323(13):1239-42.

4. Chung TW, Sridhar S, Zhang AJ, Chan KH, Li HL, Wong FK, Ng MY, Tsang RK, Lee AC, Fan Z, Ho RS, Luk SY, Kan WK, Lam SH, Wu AK, Leung SM, Chan WM, Ng PY, To KK, Cheng VC, Lung KC, Hung IF, Yuen KY. Olfactory Dysfunction in Coronavirus Disease 2019 Patients: Observational Cohort Study and Systematic Review. Open Forum Infect Dis. 2020 Jun;7(6):ofaa199. PMC7284010

5. Liao D, Zhou F, Luo L, Xu M, Wang H, Xia J, Gao Y, Cai L, Wang Z, Yin P, Wang Y, Tang L, Deng J, Mei H, Hu Y. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol. 2020 Sep;7(9):e671-e8. PMC7351397

6. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020 Oct;26(10):1636-43. PMC7869028

7. Yousaf AR, Cortese MM, Taylor AW, Broder KR, Oster ME, Wong JM, Guh AY, McCormick DW, Kamidani S, Schlaudecker EP, Edwards KM, Creech CB, Staat MA, Belay ED, Marquez P, Su JR, Salzman MB, Thompson D, Campbell AP. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation. Lancet Child Adolesc Health. 2022 Feb 22. PMC8864018

8. De Rose DU, Pugnaloni F, Calì M, Ronci S, Caoci S, Maddaloni C, Martini L, Santisi A, Dotta A, Auriti C. Multisystem Inflammatory Syndrome in Neonates Born to Mothers with SARS-CoV-2 Infection (MIS-N) and in Neonates and Infants Younger Than 6 Months with Acquired COVID-19 (MIS-C): A Systematic Review. Viruses. 2022;14(4):750.

9. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. Bmj. 2021 Jul 26;374:n1648.

10. Su Y, Yuan D, Chen, D.G., Ng, R.H., Wang, K., Choi, J., Li, S., Hong, S.,, Zhang R, Xie, J., Kornilov, S.A., Scherler, K., Pavlovitch-Bedzyk, A.J., Dong, S., Lausted, C., Lee, I.,, Fallen S, Dai, C.L., Baloni, P., Smith, B., Duvvuri, V.R., Anderson, K.G., Li, J., Yang, F., Duncombe,, C.J. M, D.J., Rostomily, C., Troisch, P., Zhou, J., Mackay, S., DeGottardi, Q., May, D.H,, Taniguchi R, Gittelman, R.M, Klinger, M., Snyder, T.M, Roper, R., Wojciechowska, G., Murray, K.,, Edmark R, Evans, S., Jones, L., Zhou, Y., Rowen, L., Liu, R., Chour, W., Algren, H.A, Berrington,, W.R. W, J.A., Cochran, R.A., Micikas, M.E., the ISB-Swedish COVID19 Biobanking Unit, Terri Wrin, Petropoulos, C.J., Cole, H.R., Fischer, T.D., Wei, W., Hoon, D.S.B., Price, N.D., Subramanian, N.,, Hill JA, Hadlock, J., Magis, A.T., Ribas, A., Lanier, L.L., Boyd, S.D., Bluestone, J.A., Chu, H., Hood,, L. G, R., Greenberg, P.D., Davis, M.M., Goldman, J.D., Heath, J.R.,. Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae. Cell. 2022.

11. Hanidziar D, Bittner EA. Hypotension, Systemic Inflammatory Response Syndrome, and COVID-19: A Clinical Conundrum. Anesth Analg. 2020 Sep;131(3):e175-e6. PMC7302068

12. Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, Lim PB. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin Med (Lond). 2021 Jan;21(1):e63-e7. PMC7850225

13. Koudelka M, Sovová E. COVID-19 Causing Hypotension in Frail Geriatric Hypertensive Patients? Medicina (Kaunas). 2021 Jun 18;57(6). PMC8235779

14. Hillmeister P, Persson PB. The Kallikrein–Kinin system. Acta Physiologica. 2012;206(4):215-9.

15. Bekassy Z, Lopatko Fagerström I, Bader M, Karpman D. Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation. Nat Rev Immunol. 2022 Jul;22(7):411-28. PMC8579187

16. Martens CP, Van Mol P, Wauters J, Wauters E, Gangnus T, Noppen B, Callewaert H, Feyen JHM, Liesenborghs L, Heylen E, Jansen S, Pereira LCV, Kraisin S, Guler I, Engelen MM, Ockerman A, Van Herck A, Vos R, Vandenbriele C, Meersseman P, Hermans G, Wilmer A, Martinod K, Burckhardt BB, Vanhove M, Jacquemin M, Verhamme P, Neyts J, Vanassche T. Dysregulation of the kallikrein-kinin system in bronchoalveolar lavage fluid of patients with severe COVID-19. eBioMedicine. 2022 2022/09/01/;83:104195.

17. Carvalho PRd, Sirois P, Fernandes PD. The role of kallikrein-kinin and renin-angiotensin systems in COVID-19 infection. Peptides. 2021 2021/01/01/;135:170428.

18. Tramontano A, Janda KD, Lerner RA. Catalytic antibodies. Science. 1986 Dec 19;234(4783):1566-70.

19. Pollack SJ, Jacobs JW, Schultz PG. Selective chemical catalysis by an antibody. Science. 1986 Dec 19;234(4783):1570-3.

20. Hilvert D. Critical analysis of antibody catalysis. Annu Rev Biochem. 2000;69:751-93.

21. Bar-Even A, Noor E, Savir Y, Liebermeister W, Davidi D, Tawfik DS, Milo R. The moderately efficient enzyme: evolutionary and physicochemical trends shaping enzyme parameters. Biochemistry. 2011 May 31;50(21):4402-10.

22. Paul S, Volle DJ, Beach CM, Johnson DR, Powell MJ, Massey RJ. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science. 1989 Jun 9;244(4909):1158-62.

23. Shuster AM, Gololobov GV, Kvashuk OA, Bogomolova AE, Smirnov IV, Gabibov AG. DNA hydrolyzing autoantibodies. Science. 1992 May 1;256(5057):665-7.

24. Paul S, Li L, Kalaga R, Wilkins-Stevens P, Stevens FJ, Solomon A. Natural catalytic antibodies: peptide-hydrolyzing activities of Bence Jones proteins and VL fragment. J Biol Chem. 1995 Jun 23;270(25):15257-61.

25. Thiagarajan P, Dannenbring R, Matsuura K, Tramontano A, Gololobov G, Paul S. Monoclonal antibody light chain with prothrombinase activity. Biochemistry. 2000 May 30;39(21):6459-65.

26. Wootla B, Dasgupta S, Dimitrov JD, Bayry J, Lévesque H, Borg JY, Borel-Derlon A, Rao DN, Friboulet A, Kaveri SV, Lacroix-Desmazes S. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia. J Immunol. 2008 Jun 1;180(11):7714-20.

27. Lacroix-Desmazes S, Moreau A, Sooryanarayana, Bonnemain C, Stieltjes N, Pashov A, Sultan Y, Hoebeke J, Kazatchkine MD, Kaveri SV. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med. 1999 Sep;5(9):1044-7.

28. Ponomarenko NA, Durova OM, Vorobiev, II, Belogurov AA, Jr., Kurkova IN, Petrenko AG, Telegin GB, Suchkov SV, Kiselev SL, Lagarkova MA, Govorun VM, Serebryakova MV, Avalle B, Tornatore P, Karavanov A, Morse HC, 3rd, Thomas D, Friboulet A, Gabibov AG. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):281-6. PMC1324791

29. Ponomarenko NA, Vorobiev, II, Alexandrova ES, Reshetnyak AV, Telegin GB, Khaidukov SV, Avalle B, Karavanov A, Morse HC, 3rd, Thomas D, Friboulet A, Gabibov AG. Induction of a protein-targeted catalytic response in autoimmune prone mice: antibody-mediated cleavage of HIV-1 glycoprotein GP120. Biochemistry. 2006 Jan 10;45(1):324-30.

30. Avalle B, Mistro D, Thomas D, Friboulet A. Polyclonal catalytic anti-idiotypic antibodies with a beta-lactamase activity. Ann N Y Acad Sci. 1996 Oct 12;799:172-5.

31. Friboulet A, Izadyar L, Avalle B, Roseto A, Thomas D. Abzyme generation using an anti-idiotypic antibody as the "internal image" of an enzyme active site. Appl Biochem Biotechnol. 1994 May-Jun;47(2-3):229-37; discussion 37-9.

32. Izadyar L, Friboulet A, Remy MH, Roseto A, Thomas D. Monoclonal anti-idiotypic antibodies as functional internal images of enzyme active sites: production of a catalytic antibody with a cholinesterase activity. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8876-80. PMC47463

33. Friboulet A, Izadyar L, Avalle B, Roseto A, Thomas D. Antiidiotypic antibodies as functional internal images of enzyme-active sites. Ann N Y Acad Sci. 1995 Mar 31;750:265-70.

34. Ponomarenko NA, Pillet D, Paon M, Vorobiev, II, Smirnov IV, Adenier H, Avalle B, Kolesnikov AV, Kozyr AV, Thomas D, Gabibov AG, Friboulet A. Anti-idiotypic antibody mimics proteolytic function of parent antigen. Biochemistry. 2007 Dec 18;46(50):14598-609.

35. Brooks B, Tancredi C, Song Y, Mogus AT, Huang M-LW, Zhu H, Phan TL, Zhu H, Kadl A, Woodfolk J. Epstein–Barr Virus and Human Herpesvirus-6 Reactivation in Acute COVID-19 Patients. Viruses. 2022;14(9):1872.

36. García-Escobar A, Vera-Vera S, Jurado-Román A, Jiménez-Valero S, Galeote G, Moreno R. Calcium Signaling Pathway Is Involved in the Shedding of ACE2 Catalytic Ectodomain: New Insights for Clinical and Therapeutic Applications of ACE2 for COVID-19. Biomolecules. 2022 Jan 5;12(1). PMC8774087

37. Arthur JM, Forrest JC, Boehme KW, Kennedy JL, Owens S, Herzog C, Liu J, Harville TO. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS One. 2021;16(9):e0257016. PMC8415618

38. Tanna A, Guarino L, Tam FWK, Rodriquez-Cubillo B, Levy JB, Cairns TD, Griffith M, Tarzi RM, Caplin B, Salama AD, Cook T, Pusey CD. Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. Nephrology Dialysis Transplantation. 2014;30(7):1185-92.

39. Xiao F, Burns KD. Measurement of angiotensin converting enzyme 2 activity in biological fluid (ACE2). Hypertension: Springer; 2017. p. 101-15.